Opinion Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Mar 24, 2021; 12(3): 144-149
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.144
Cardiovascular risk management in cancer survivors: Are we doing it right?
Turab Mohammed, Tarang Parekh, Aakash Desai
Turab Mohammed, Department of Medicine, University of Connecticut, Farmington, CT 06030, United States
Tarang Parekh, Department of Health Administration and Policy, George Mason University, Fairfax, VA 22030, United States
Aakash Desai, Department of Hematology and Oncology, Mayo Clinic, Rochester, MN 55902, United States
Author contributions: Mohammed T and Desai A contributed to the conception and design, provision of study material or patients; all authors contributed to the collection and assembly of data, data analysis, and interpretation of manuscript writing and final approval of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Aakash Desai, MBBS, Postdoctoral Fellow, Department of Hematology and Oncology, Mayo Clinic, Rochester, MN 55902, United States. adesaimd@outlook.com
Received: December 16, 2020
Peer-review started: December 16, 2020
First decision: January 7, 2021
Revised: January 12, 2021
Accepted: February 12, 2021
Article in press: February 12, 2021
Published online: March 24, 2021
Processing time: 84 Days and 21.7 Hours
Core Tip

Core Tip: Accurate assessment of cardiovascular risk in adult cancer survivors is important. Cancer survivors form a unique subset of a vulnerable population given their exposures to potential cardiotoxic therapies. The importance of common preventive cardiovascular strategies in the long-term outcomes of cancer survivors is understated in clinical practice.